Immatics (IMTX) Shares Outstanding (2020 - 2025)
Immatics recorded quarterly Shares Outstanding of $156.1 million in Q4 2025, up 20.15% quarter-over-quarter from $129.9 million in Q4 2024, and up 20.15% year-over-year from $129.9 million in Q4 2024.
Immatics' Shares Outstanding history runs 6 years deep, the most recent figure standing at $156.1 million for Q4 2025.
- In Q4 2025, Shares Outstanding rose 20.15% year-over-year to $156.1 million; the TTM figure through Dec 2025 stood at $156.1 million (up 20.15% YoY), while the FY2025 annual figure was $151.5 million, up 16.62% from the prior year.
- Shares Outstanding came in at $156.1 million for Q4 2025 at Immatics, up from $129.9 million in the prior quarter.
- In the past five years, Shares Outstanding ranged from a high of $156.1 million in Q4 2025 to a low of $72.0 million in Q4 2021.
- A 5-year average of $105.4 million and a median of $91.1 million in 2023 frame the typical range for Shares Outstanding.
- Across the five-year window, Shares Outstanding retreated 4.02% in 2021 and jumped 42.6% in 2024, its largest moves.
- Immatics' Shares Outstanding stood at $72.0 million in 2021, then increased by 8.66% to $78.2 million in 2022, then grew by 16.44% to $91.1 million in 2023, then surged by 42.6% to $129.9 million in 2024, then increased by 20.15% to $156.1 million in 2025.
- According to Business Quant data, Shares Outstanding over the past three periods registered $156.1 million, $129.9 million, and $91.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 5.21 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 56.35 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 91.57 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.16 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.80 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 133.44 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 156.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2025 | 156.06 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2024 | 129.89 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2023 | 91.09 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2022 | 78.22 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2021 | 71.99 Mn |
| Dec 31, 2020 | 75.01 Mn |
| Dec 31, 2020 | 75.01 Mn |
| Dec 31, 2020 | 75.01 Mn |
| Dec 31, 2020 | 75.01 Mn |
| Dec 31, 2020 | 75.01 Mn |
| Dec 31, 2020 | 75.01 Mn |
| Dec 31, 2020 | 75.01 Mn |
| Dec 31, 2020 | 75.01 Mn |